Dennis

Real TAKHZYRO Patient since 2018

This is my TAKHZYRO
EXPERIENCE

Imagine what the #1 PRESCRIBED HAE preventive treatment* can mean for your patients

TAKHZYRO is clinically proven to help prevent HAE attacks, and patients experienced long-term freedom from attacks for an average of 14.8 months.^1,2

Evaluated in a 6.5-month study and a 2.5-year open-label extension (OLE) study
Mean duration of the attack-free period in the OLE study was 14.8 (SD=12.4) months (N=209)

*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data. †The number of patients prescribed TAKHZYRO is based on third-party US specialty pharmacy data.

I want to learn about:

efficacy

safety

dosing

Rediscover effective prevention

The safety and efficacy of TAKHZYRO (lanadelumab-flyo) were assessed in a 6.5 months pivotal trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo.^1,4

help study design

Significant reduction in mean attack rate^‡ vs placebo at 6.5 months in the HELP study^1,4

87% reduction in attacks vs placebo (Adjusted P<0.001)

TAKHZYRO 300 mg every 4 weeks resulted in a 73% reduction in attacks vs placebo (Adjusted P<0.001)^1§

Mean monthly attack rate during the run-in period⁴:

3.52
for Q2W arm (n=27)

3.71
for Q4W arm (n=29)

4.02
for placebo arm (n=41)

Mean monthly attack rate during the treatment period¹:

0.26
for Q2W arm

0.53
for Q4W arm

1.97
for placebo arm

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.¹
^‡Mean monthly attack rate: number of attacks/4 weeks.¹
^§Adjusted P-values for multiple testing.¹

Q2W=every 2 weeks; Q4W=every 4 weeks.

HELP study: A multicenter, double-blind, parallel group, placebo-controlled clinical study assessed the efficacy and safety of TAKHZYRO in 125 HAE Type I/II patients (≥12 years of age) for 6.5 months. Patients were treated with TAKHZYRO 150 mg q4wks, TAKHZYRO 300 mg q2wks, TAKHZYRO 300 mg q4wks, or placebo. Primary endpoint: rate of investigator-confirmed attacks during the treatment.^1,4

The 6.5-month HELP clinical trial of 125 patients led to the 2018 FDA approval of TAKHZYRO

STUDIED IN OVER

800

PATIENTS GLOBALLY³
ACROSS 15 STUDIES

STUDIED FOR

11

YEARS IN US CLINICAL AND REAL-WORLD STUDIES³

PRESCRIBED TO OVER

4000

US PATIENTS SINCE 2018^3‖

^||Based on third-party US specialty
pharmacy data.

Help your patients get started and stay on track with TAKHZYRO.

patient resources

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2023. 2. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Allergy. 2022;77(3):979-990. doi:10.1111/all.15011 3. Data on File, TAKHZYRO DOF, Takeda Pharmaceuticals USA, Inc. 4. Banerji A, Riedl MA, Bernstein JA, et al. JAMA. 2018;320(20):2108-2121. doi:10.1001/jama.2018.16773

https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/hcp/fragments/isi

This is my TAKHZYROEXPERIENCE